The Prevalence of Antifungal Agents Administration in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: a Retrospective Study
Background: Invasive fungal infections (IFIs) are chief infectious complications in patients undergoing hematopoietic stem cell transplantation (HSCT). However, the diagnosis of fungal infections is difficult, and often empiric treatment initiates. Since there is no data available on the prevalence...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Tehran University of Medical Sciences
2013-07-01
|
Series: | International Journal of Hematology-Oncology and Stem Cell Research |
Subjects: | |
Online Access: | http://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/397/414 |
id |
doaj-8abb7eff4294426aafe861762e1f3c6f |
---|---|
record_format |
Article |
spelling |
doaj-8abb7eff4294426aafe861762e1f3c6f2020-11-25T03:56:18ZengTehran University of Medical SciencesInternational Journal of Hematology-Oncology and Stem Cell Research2008-30092008-22072013-07-017318The Prevalence of Antifungal Agents Administration in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: a Retrospective StudyMona KargarAlireza AhmadvandMilad AhmadvandMolouk HadjibabaieKheirollah GholamiSeyed Hamid KhoeeMohammad Reza JavadiArdeshir GhavamzadehBackground: Invasive fungal infections (IFIs) are chief infectious complications in patients undergoing hematopoietic stem cell transplantation (HSCT). However, the diagnosis of fungal infections is difficult, and often empiric treatment initiates. Since there is no data available on the prevalence of antifungal drugs administration in allogeneic HSCT recipients in Iran, we decided to conduct this study.Methods: This study was a retrospective review of records of patients who received allogeneic HSCT in the Hematology-Oncology, Bone Marrow Transplantation center at Shariati Hospital in Tehran, between August 2009 and August 2010.Results: Sixty (73.1%) patients consist of 41 men (68.3%) with mean age of 26.3 (± 1.2) years received allogeneic HSCT. Patients received prophylaxis with fulconazole however; in 28 patients (46.7%) it was switched to low dose amphotericin B. Fifteen patients (25%) received treatment with antifungal agents. Amphotericin B was the empiric agent administered. In 3 patients treatment was switched to voriconazole. Neither positive culture nor direct microscopic evidence was available from the obtained specimen. Only in one patient the result of serum galactomannan assay was positive. There were no significant differences in neutropenia duration (P value: 0.54), length of hospital stay (P value: 0.27) and number of patients developed graft versus host disease (P value: 0.07) between patients received antifungal agents with those who did not receive treatment.Conclusion: In this study HSCT recipients received antifungal agents for prophylaxis. Twenty five percent of patients received treatment with antifungal agents empirically. Improvement in diagnosis of these infections can be helpful and lead to targeted therapy. We suggest larger prospective trials for better assessment of antifungal agent administration.http://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/397/414Antifungal AgentsPeripheral Blood Stem Cell TransplantationRetrospective StudiesAmphotericin B |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mona Kargar Alireza Ahmadvand Milad Ahmadvand Molouk Hadjibabaie Kheirollah Gholami Seyed Hamid Khoee Mohammad Reza Javadi Ardeshir Ghavamzadeh |
spellingShingle |
Mona Kargar Alireza Ahmadvand Milad Ahmadvand Molouk Hadjibabaie Kheirollah Gholami Seyed Hamid Khoee Mohammad Reza Javadi Ardeshir Ghavamzadeh The Prevalence of Antifungal Agents Administration in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: a Retrospective Study International Journal of Hematology-Oncology and Stem Cell Research Antifungal Agents Peripheral Blood Stem Cell Transplantation Retrospective Studies Amphotericin B |
author_facet |
Mona Kargar Alireza Ahmadvand Milad Ahmadvand Molouk Hadjibabaie Kheirollah Gholami Seyed Hamid Khoee Mohammad Reza Javadi Ardeshir Ghavamzadeh |
author_sort |
Mona Kargar |
title |
The Prevalence of Antifungal Agents Administration in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: a Retrospective Study |
title_short |
The Prevalence of Antifungal Agents Administration in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: a Retrospective Study |
title_full |
The Prevalence of Antifungal Agents Administration in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: a Retrospective Study |
title_fullStr |
The Prevalence of Antifungal Agents Administration in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: a Retrospective Study |
title_full_unstemmed |
The Prevalence of Antifungal Agents Administration in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: a Retrospective Study |
title_sort |
prevalence of antifungal agents administration in patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective study |
publisher |
Tehran University of Medical Sciences |
series |
International Journal of Hematology-Oncology and Stem Cell Research |
issn |
2008-3009 2008-2207 |
publishDate |
2013-07-01 |
description |
Background: Invasive fungal infections (IFIs) are chief infectious complications in patients undergoing hematopoietic stem cell transplantation (HSCT). However, the diagnosis of fungal infections is difficult, and often empiric treatment initiates. Since there is no data available on the prevalence of antifungal drugs administration in allogeneic HSCT recipients in Iran, we decided to conduct this study.Methods: This study was a retrospective review of records of patients who received allogeneic HSCT in the Hematology-Oncology, Bone Marrow Transplantation center at Shariati Hospital in Tehran, between August 2009 and August 2010.Results: Sixty (73.1%) patients consist of 41 men (68.3%) with mean age of 26.3 (± 1.2) years received allogeneic HSCT. Patients received prophylaxis with fulconazole however; in 28 patients (46.7%) it was switched to low dose amphotericin B. Fifteen patients (25%) received treatment with antifungal agents. Amphotericin B was the empiric agent administered. In 3 patients treatment was switched to voriconazole. Neither positive culture nor direct microscopic evidence was available from the obtained specimen. Only in one patient the result of serum galactomannan assay was positive. There were no significant differences in neutropenia duration (P value: 0.54), length of hospital stay (P value: 0.27) and number of patients developed graft versus host disease (P value: 0.07) between patients received antifungal agents with those who did not receive treatment.Conclusion: In this study HSCT recipients received antifungal agents for prophylaxis. Twenty five percent of patients received treatment with antifungal agents empirically. Improvement in diagnosis of these infections can be helpful and lead to targeted therapy. We suggest larger prospective trials for better assessment of antifungal agent administration. |
topic |
Antifungal Agents Peripheral Blood Stem Cell Transplantation Retrospective Studies Amphotericin B |
url |
http://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/397/414 |
work_keys_str_mv |
AT monakargar theprevalenceofantifungalagentsadministrationinpatientsundergoingallogeneichematopoieticstemcelltransplantationaretrospectivestudy AT alirezaahmadvand theprevalenceofantifungalagentsadministrationinpatientsundergoingallogeneichematopoieticstemcelltransplantationaretrospectivestudy AT miladahmadvand theprevalenceofantifungalagentsadministrationinpatientsundergoingallogeneichematopoieticstemcelltransplantationaretrospectivestudy AT moloukhadjibabaie theprevalenceofantifungalagentsadministrationinpatientsundergoingallogeneichematopoieticstemcelltransplantationaretrospectivestudy AT kheirollahgholami theprevalenceofantifungalagentsadministrationinpatientsundergoingallogeneichematopoieticstemcelltransplantationaretrospectivestudy AT seyedhamidkhoee theprevalenceofantifungalagentsadministrationinpatientsundergoingallogeneichematopoieticstemcelltransplantationaretrospectivestudy AT mohammadrezajavadi theprevalenceofantifungalagentsadministrationinpatientsundergoingallogeneichematopoieticstemcelltransplantationaretrospectivestudy AT ardeshirghavamzadeh theprevalenceofantifungalagentsadministrationinpatientsundergoingallogeneichematopoieticstemcelltransplantationaretrospectivestudy AT monakargar prevalenceofantifungalagentsadministrationinpatientsundergoingallogeneichematopoieticstemcelltransplantationaretrospectivestudy AT alirezaahmadvand prevalenceofantifungalagentsadministrationinpatientsundergoingallogeneichematopoieticstemcelltransplantationaretrospectivestudy AT miladahmadvand prevalenceofantifungalagentsadministrationinpatientsundergoingallogeneichematopoieticstemcelltransplantationaretrospectivestudy AT moloukhadjibabaie prevalenceofantifungalagentsadministrationinpatientsundergoingallogeneichematopoieticstemcelltransplantationaretrospectivestudy AT kheirollahgholami prevalenceofantifungalagentsadministrationinpatientsundergoingallogeneichematopoieticstemcelltransplantationaretrospectivestudy AT seyedhamidkhoee prevalenceofantifungalagentsadministrationinpatientsundergoingallogeneichematopoieticstemcelltransplantationaretrospectivestudy AT mohammadrezajavadi prevalenceofantifungalagentsadministrationinpatientsundergoingallogeneichematopoieticstemcelltransplantationaretrospectivestudy AT ardeshirghavamzadeh prevalenceofantifungalagentsadministrationinpatientsundergoingallogeneichematopoieticstemcelltransplantationaretrospectivestudy |
_version_ |
1724465770402938880 |